Overexpression of Jak1 Activating Mutants in Hepatocytes Is Insufficient to Generate Hepatocellular Carcinoma in Zebrafish

Yue Yuan; Jian Zhang; Qin Zhou

doi:10.1016/j.jgg.2015.11.003

Volume 43 Issue 2

Feb. 2016

Turn off MathJax

Article Contents

Article Navigation > Journal of Genetics and Genomics > 2016 > 43(2): 99-102

PDF( 1059 KB)

Overexpression of Jak1 Activating Mutants in Hepatocytes Is Insufficient to Generate Hepatocellular Carcinoma in Zebrafish

doi: 10.1016/j.jgg.2015.11.003

a
The Division of Molecular Nephrology and the Creative Training Center for Undergraduates, the M.O.E. Key Laboratory of Laboratory Medical Diagnostics, the College of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, China
b
State Key Laboratory of Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China

More Information

Corresponding author: E-mail address: jianzhang84@genetics.ac.cn (Jian Zhang); E-mail address: zhouqin@cqmu.edu.cn (Qin Zhou)
Received Date: 2015-09-14
Accepted Date: 2015-11-08
Rev Recd Date: 2015-10-28

Available Online: 2016-01-22

Publish Date: 2016-02-20

Abstract

FullText(HTML)

References(14)

References

[1]	Farazi, P.A., DePinho, R.A. Hepatocellular carcinoma pathogenesis: from genes to environment Nat. Rev. Cancer, 6 (2006),pp. 674-687
[2]	Fatima, S., Lee, N.P., Luk, J.M. Dickkopfs and Wnt/β-catenin signaling in liver cancer World J. Clin. Oncol., 2 (2011),pp. 311-325
[3]	He, G., Karin, M. NF-κB and STAT3 – key players in liver inflammation and cancer Cell Res., 21 (2011),pp. 159-168
[4]	Hong, S., Laimins, L.A. The JAK-STAT transcriptional regulator, STAT-5, activates the ATM DNA damage pathway to induce HPV 31 genome amplification upon epithelial differentiation PLoS Pathog., 9 (2013),p. e1003295
[5]	Hsu, I.C., Metcalf, R.A., Sun, T. et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas Nature, 350 (1991),pp. 427-428
[6]	Hussain, S.P., Schwank, J., Staib, F. et al. Oncogene, 26 (2007),pp. 2166-2176
[7]	Jemal, A., Bray, F., Center, M.M. et al. Global cancer statistics CA Cancer J. Clin., 61 (2011),pp. 69-90
[8]	Kan, Z., Zheng, H., Liu, X. et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma Genome Res., 23 (2013),pp. 1422-1433
[9]	Liberzon, A., Subramanian, A., Pinchback, R. et al. Molecular signatures database (MSigDB) 3.0 Bioinformatics, 27 (2011),pp. 1739-1740
[10]	Nguyen, A.T., Emelyanov, A., Koh, C.H. et al. Dis. Model. Mech., 4 (2011),pp. 801-813
[11]	Parkin, D.M. The global health burden of infection-associated cancers in the year 2002 Int. J. Cancer, 118 (2006),pp. 3030-3044
[12]	Vogelstein, B., Kinzler, K.W. The multistep nature of cancer Trends Genet., 9 (1993),pp. 138-141
[13]	Wei, Y., Van Nhieu, J.T., Prigent, S. et al. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, β-catenin expression, and clinical features Hepatology, 36 (2002),pp. 692-701
[14]	Whittaker, S., Marais, R., Zhu, A.X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma Oncogene, 29 (2010),pp. 4989-5005